Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Post-Mkt 03-19 18:43:46 EDT

11.10

+0.24

+2.21%

盘后11.10

+0.000.00%

18:16 EDT

High11.36	Low10.64	Vol1.27M
Open11.21	D1 Closing10.86	Amplitude6.62%
Mkt Cap1.11B	Tradable Cap960.66M	Total Shares100.36M
T/O14.02M	T/O Rate1.47%	Tradable Shares86.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":11.1,"timestamp":1773950400000,"preClose":10.86,"halted":0,"volume":1272054,"hourTrading":{"tag":"盘后","latestPrice":11.1,"preClose":11.1,"latestTime":"18:16 EDT","volume":9843,"amount":109198.63571999999,"timestamp":1773958565247,"change":0,"changeRate":0,"amplitude":0.018018},"delay":0,"changeRate":0.022099447513812175,"floatShares":86545499,"shares":100358200,"eps":-1.47,"marketStatus":"Post-Mkt","change":0.24,"latestTime":"03-19 18:43:46 EDT","open":11.21,"high":11.36,"low":10.641,"amount":14023148.73708,"amplitude":0.066206,"askPrice":11.99,"askSize":16,"bidPrice":10.67,"bidSize":13,"shortable":0,"etf":0,"ttmEps":-1.47,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773964800000},"marketStatusCode":4,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":10.86,"preHourTrading":{"tag":"盘前","latestPrice":11.25,"preClose":10.86,"latestTime":"09:11 EDT","volume":14867,"amount":165524.375959,"timestamp":1773925908092,"change":0.39,"changeRate":0.035912,"amplitude":0.069982},"postHourTrading":{"tag":"盘后","latestPrice":11.1,"preClose":11.1,"latestTime":"18:16 EDT","volume":9843,"amount":109198.63571999999,"timestamp":1773958565247,"change":0,"changeRate":0,"amplitude":0.018018},"volumeRatio":0.948818,"impliedVol":0.2714,"impliedVolPercentile":0.0438},"requestUrl":"/m/hq/s/ORIC","defaultTab":"news","newsList":[{"id":"2620405809","title":"Oric Pharmaceuticals to present rinzimetostat preclinical data at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405809","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405809?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:01","pubTimestamp":1773781311,"startTime":"0","endTime":"0","summary":"Oric will present preclinical data on rinzimetostat  at the AACR Annual Meeting in San Diego, California, taking place April 17-22, 2026. Posters are scheduled for Wednesday, April 22, 2026, 9:00 a.m.-12:00 p.m. PT, in Poster Section 14. The presentations are in the “Experimental and Molecular Therapeutics” category under the session “Novel Strategies to Reverse Drug Resistance.” Abstracts are accessible via this link.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2dlZLd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","LU2210150020.SGD","ORIC","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","BK4112","BK4585","SG9999014005.SGD","LU0314104364.USD","NDAQ","BK4139","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00BN0W2T93.GBP"],"gpt_icon":0},{"id":"2620401180","title":"ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401180","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401180?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:01","pubTimestamp":1773781260,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March  17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that addres","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257727/0/en/ORIC-Pharmaceuticals-Announces-Preclinical-Rinzimetostat-ORIC-944-Presentations-at-the-2026-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4117","AR","ORIC","AFG","BK4107","BK4139"],"gpt_icon":0},{"id":"2619104176","title":"A Look At ORIC Pharmaceuticals (ORIC) Valuation After Competitor Tazverik Withdrawal And Analyst Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2619104176","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619104176?lang=en_us&edition=fundamental","pubTime":"2026-03-15 21:24","pubTimestamp":1773581056,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (ORIC) came under pressure after Ipsen pulled cancer drug Tazverik over concerns about secondary hematologic malignancies, even though ORIC said its prostate cancer candidate rinzimetostat showed no malignancies in preclinical toxicity testing.\nSee our latest analysis for ORIC Pharmaceuticals.\nAt a share price of US$11.90, ORIC has seen a 19.12% 30 day share price return and 45.65% year to date. The 1 year total shareholder return of 52.76% and 3 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-competit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-competit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","ORIC","BK4139"],"gpt_icon":0},{"id":"2619195465","title":"Oric Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2619195465","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619195465?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:25","pubTimestamp":1773397500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2026 06:25 ET (10:25 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2618934682","title":"Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934682?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:56","pubTimestamp":1773140197,"startTime":"0","endTime":"0","summary":"Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Oric Pharmaceuticals, retaining the price target of $17.00. Yigal Nochomovitz has give...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/constructive-buy-thesis-on-oric-driven-by-differentiated-prc2-biology-and-manageable-safety-profile-for-rinzimetostat-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/constructive-buy-thesis-on-oric-driven-by-differentiated-prc2-biology-and-manageable-safety-profile-for-rinzimetostat-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2618765096","title":"Cantor says Oric move down on tazemetostat withdrawal an ‘over-reaction’","url":"https://stock-news.laohu8.com/highlight/detail?id=2618765096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618765096?lang=en_us&edition=fundamental","pubTime":"2026-03-10 01:45","pubTimestamp":1773078341,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Prakhar Agrawal notes Oric Pharmaceuticals (ORIC) shares are down 15% after Ipsen (IPSEY) announced that it is voluntaril...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cantor-says-oric-move-down-on-tazemetostat-withdrawal-an-over-reaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cantor-says-oric-move-down-on-tazemetostat-withdrawal-an-over-reaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPSEY","BK4139","BK4007","ORIC"],"gpt_icon":0},{"id":"2618162740","title":"Oric Pharmaceuticals falls after peer Ipsen voluntarily withdraws Tazverik","url":"https://stock-news.laohu8.com/highlight/detail?id=2618162740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618162740?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:00","pubTimestamp":1773068411,"startTime":"0","endTime":"0","summary":"Shares of Oric Pharmaceuticals (ORIC) are down $1.63, or 12%, to $12.09 in Monday morning trading after rival drugmaker Ipsen (IPSEY) announced tod...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-falls-after-peer-ipsen-voluntarily-withdraws-tazverik-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-falls-after-peer-ipsen-voluntarily-withdraws-tazverik-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPSEY","BK4007","BK4139","ORIC"],"gpt_icon":0},{"id":"2617658924","title":"Oric Pharmaceuticals Reports Nasdaq Inducement Equity Grants for New Employee","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658924","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658924?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:30","pubTimestamp":1772832630,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals granted inducement equity awards to one new non-executive employee, consisting of 14,800 non-qualified stock options and 2,400 restricted stock units under its 2022 Inducement Equity Incentive Plan. The options are priced at the closing share price on March 2, 2026, vesting 25% after one year and then monthly over the following three years, while the RSUs vest in three equal annual installments over three years.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL3SjqzN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","BK4588","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","ORIC","SG9999014021.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2617658959","title":"Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658959?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:30","pubTimestamp":1772832600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA5XXSBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2617658112","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658112","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658112?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:30","pubTimestamp":1772832600,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March  06, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that addres","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/06/3251331/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2614710260","title":"Oric Pharmaceuticals CFO Dominic Piscitelli Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614710260","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614710260?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:54","pubTimestamp":1772142854,"startTime":"0","endTime":"0","summary":"Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals Inc, reported a disposal of common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL2pKsnw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharmaceuticals CFO Dominic Piscitelli Disposes of Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2614703962","title":"A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2614703962","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614703962?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:35","pubTimestamp":1772033712,"startTime":"0","endTime":"0","summary":"Why ORIC Pharmaceuticals stock is back on investors’ radar\nORIC Pharmaceuticals (ORIC) has drawn fresh attention after reporting Phase 1b data for its lead cancer drugs and securing new funding that management expects will cover operations into the second half of 2028.\nSee our latest analysis for ORIC Pharmaceuticals.\nThe recent Phase 1b readouts, extended cash runway into late 2028 and new equity programs have all landed alongside a strong 64.26% year to date share price return. The 3 year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-phase-1b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2614374552","title":"Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2614374552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614374552?lang=en_us&edition=fundamental","pubTime":"2026-02-24 23:55","pubTimestamp":1771948536,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $23 and keeps a Buy rating on the sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-raised-to-25-from-23-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-raised-to-25-from-23-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2613743094","title":"Oric Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $25 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2613743094","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613743094?lang=en_us&edition=fundamental","pubTime":"2026-02-24 23:51","pubTimestamp":1771948303,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nAZN4SI14U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2613352717","title":"Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2613352717","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613352717?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:01","pubTimestamp":1771941660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 09:01 ET (14:01 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2613771467","title":"Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613771467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613771467?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:16","pubTimestamp":1771938973,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Oric Pharmaceuticals today and set a price target of $15.00. According to TipRanks, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","ORIC"],"gpt_icon":0},{"id":"2613122755","title":"Oric Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2613122755","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613122755?lang=en_us&edition=fundamental","pubTime":"2026-02-24 07:15","pubTimestamp":1771888506,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryOric Pharmaceuticals Inc ORIC.OQ reported a quarterly adjusted loss of 30 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL8N3ZJ2HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2613675550","title":"Oric Pharmaceuticals Launches New 2026 ATM Share Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2613675550","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613675550?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:53","pubTimestamp":1771887228,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals ( ($ORIC) ) just unveiled an update. On May 6, 2021, ORIC Pharmaceuticals, Inc. entered into an Open Market Sale Agreement wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oric-pharmaceuticals-launches-new-2026-atm-share-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oric-pharmaceuticals-launches-new-2026-atm-share-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2613536047","title":"Oric Pharmaceuticals - May Offer & Sell Shares of Common Stock of up to $200 Mln From Time to Time Through Jefferies - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2613536047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613536047?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:26","pubTimestamp":1771885560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZJ120:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2613475380","title":"ORIC Pharmaceuticals Q4 EPS $(0.30) Beats $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2613475380","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613475380?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:17","pubTimestamp":1771885053,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.7 percent. This is a 41.18 percent increase over losses of $(0.51) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50802492/oric-pharmaceuticals-q4-eps-0-30-beats-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ORIC Pharmaceuticals Q4 EPS $(0.30) Beats $(0.37) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":-0.1374},{"period":"1month","weight":0.0871},{"period":"3month","weight":0.3432},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.4233},{"period":"ytd","weight":0.3276}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.114566},{"month":4,"riseRate":0.2,"avgChangeRate":-0.164176},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07899},{"month":6,"riseRate":0.666667,"avgChangeRate":0.141043},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.000511},{"month":8,"riseRate":0.666667,"avgChangeRate":0.090659},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}